Filter

Refine by collections

  • Growth Hormone in Endocrine Cancers (3)

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 1 - 3 of 3 items for :

  • neuroendocrine carcinoma x
  • Growth Hormone in Endocrine Cancers x
  • Refine by access: All content x
Clear All
Yue Wang Liggins Institute, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand

Search for other papers by Yue Wang in
Google Scholar
PubMed Close
,
Stephen M F Jamieson Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand
Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand

Search for other papers by Stephen M F Jamieson in
Google Scholar
PubMed Close
, and
Jo K Perry Liggins Institute, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand

Search for other papers by Jo K Perry in
Google Scholar
PubMed Close

cancer. Good clinical correlations are observed for cancers such as breast, endometrial, melanoma and hepatocellular carcinoma (HCC) ( Wu et al. 2011 , Sustarsic et al. 2013 , Kong et al. 2016 , Perry et al. 2017 , Kaseb et al. 2022

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-23-0033
Volume/Issue:
Volume 30: Issue 9
Free access
Christopher A Galifi Department of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling and Cancer Institute of New Jersey, Rutgers Biomedical and Health Sciences, Newark, New Jersey, United States

Search for other papers by Christopher A Galifi in
Google Scholar
PubMed Close
and
Teresa L Wood Department of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling and Cancer Institute of New Jersey, Rutgers Biomedical and Health Sciences, Newark, New Jersey, United States

Search for other papers by Teresa L Wood in
Google Scholar
PubMed Close

model was sufficient to convert poorly metastatic tumors to a highly metastatic carcinoma ( Rota et al. 2014 , Obr et al. 2018 , Obr et al. 2022 ). These findings support a dual role for IGF1R in both tumor promotion and suppression and are

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-23-0031
Volume/Issue:
Volume 30: Issue 10
Free access
Zvi Laron Endocrinology and Diabetes Research Unit, Schneider Children’s Medical Center, Petah Tikva, Israel

Search for other papers by Zvi Laron in
Google Scholar
PubMed Close
and
Haim Werner Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Search for other papers by Haim Werner in
Google Scholar
PubMed Close

& Giandomenico V 2013 Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas . European Journal of Endocrinology 168 253 – 261 . ( https://doi.org/10.1530/EJE-12-0814 ) Dauber A Muñoz-Calvo MT

Article Type:
Review Article
Collections:
Growth Hormone in Endocrine Cancers
DOI:
https://doi.org/10.1530/ERC-22-0394
Volume/Issue:
Volume 30: Issue 9
Free access